Gastric Cancer | Specialty

FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer

February 20th 2025

SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.

Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer

January 26th 2025

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis

January 24th 2025

Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.

Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer

January 24th 2025

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer

January 23rd 2025

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

Dr Strickler on the Rationale for Evaluating Telisotuzumab Adizutecan in Gastric/GEJ Cancer

January 13th 2025

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or Metastatic Gastric/GEJ Cancer

December 27th 2024

The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

November 27th 2024

Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

November 20th 2024

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

November 5th 2024

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Dr Rutkowski on the Safety Profile of Avelumab Plus Axitinib in GIST

October 31st 2024

Piotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST

Dr Pabon on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

October 31st 2024

Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.

Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.

Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

October 25th 2024

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma

October 18th 2024

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma

October 18th 2024

The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

October 7th 2024

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.